<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335612</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2099</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092099</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Chemerin is an adipokine involved in inflammatory and metabolic diseases, and its circulating levels have been associated with inflammatory parameters in various patient cohorts. Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, which causes COVID-19, triggers inflammatory pathways. However, the association between serum chemerin levels and COVID-19 disease severity and outcomes has not been definitively established.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, serum chemerin levels were analyzed in 64 patients with moderate COVID-19 and 60 patients with severe disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that serum chemerin levels were comparable between these two groups and slightly higher than in healthy controls. Notably, COVID-19 patients with hypertension exhibited elevated serum chemerin levels, while those with liver cirrhosis had lower levels. When patients with these comorbidities were excluded from the analyses, serum chemerin levels in COVID-19 patients were similar to those in healthy controls. Positive correlations were observed between serum chemerin levels and markers such as alkaline phosphatase, C-reactive protein, eosinophils, and lymphocytes in the entire cohort, as well as in the subgroup excluding patients with hypertension and cirrhosis. Additionally, urinary chemerin levels were comparable between COVID-19 patients and controls, and neither hypertension nor dialysis significantly affected urinary chemerin levels. Both survivors and non-survivors had similar serum and urinary chemerin levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, this study suggests that comorbidities such as arterial hypertension and liver cirrhosis do have a more significant impact on serum chemerin levels than SARS-CoV-2 infection itself.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pavel</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9473-3509</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amend</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidtner</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utrata</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birner</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2222-2926</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krautbauer</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mester</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buechler</LastName><ForeName>Christa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5635-3994</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">ventilation</Keyword></KeywordList><CoiStatement>The authors do not have a conflict of interest pertinent to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335612</ArticleId><ArticleId IdType="pmc">PMC11430512</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092099</ArticleId><ArticleId IdType="pii">biomedicines12092099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wittamer V., Bondue B., Guillabert A., Vassart G., Parmentier M., Communi D. Neutrophil-mediated maturation of chemerin: A link between innate and adaptive immunity. J. Immunol. 2005;175:487–493. doi: 10.4049/jimmunol.175.1.487.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.1.487</ArticleId><ArticleId IdType="pubmed">15972683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G., Walder K., Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687–4694. doi: 10.1210/en.2007-0175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2007-0175</ArticleId><ArticleId IdType="pubmed">17640997</ArticleId></ArticleIdList></Reference><Reference><Citation>Buechler C., Feder S., Haberl E.M., Aslanidis C. Chemerin Isoforms and Activity in Obesity. Int. J. Mol. Sci. 2019;20:1128. doi: 10.3390/ijms20051128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20051128</ArticleId><ArticleId IdType="pmc">PMC6429392</ArticleId><ArticleId IdType="pubmed">30841637</ArticleId></ArticleIdList></Reference><Reference><Citation>Goralski K.B., McCarthy T.C., Hanniman E.A., Zabel B.A., Butcher E.C., Parlee S.D., Muruganandan S., Sinal C.J. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 2007;282:28175–28188. doi: 10.1074/jbc.M700793200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M700793200</ArticleId><ArticleId IdType="pubmed">17635925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Luo S., Wang G., Peng Z., Zeng W., Tan S., Xi Y., Fan J. Downregulation of tazarotene induced gene-2 (TIG2) in skin squamous cell carcinoma. Eur. J. Dermatol. 2008;18:638–641.</Citation><ArticleIdList><ArticleId IdType="pubmed">18955196</ArticleId></ArticleIdList></Reference><Reference><Citation>Goralski K.B., Jackson A.E., McKeown B.T., Sinal C.J. More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer. Int. J. Mol. Sci. 2019;20:4778. doi: 10.3390/ijms20194778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194778</ArticleId><ArticleId IdType="pmc">PMC6801800</ArticleId><ArticleId IdType="pubmed">31561459</ArticleId></ArticleIdList></Reference><Reference><Citation>Banas M., Zabieglo K., Kasetty G., Kapinska-Mrowiecka M., Borowczyk J., Drukala J., Murzyn K., Zabel B.A., Butcher E.C., Schroeder J.M., et al. Chemerin is an antimicrobial agent in human epidermis. PLoS ONE. 2013;8:e58709. doi: 10.1371/annotation/4dfd522c-f0fd-40db-aadc-44cbef367a40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/4dfd522c-f0fd-40db-aadc-44cbef367a40</ArticleId><ArticleId IdType="pmc">PMC3604073</ArticleId><ArticleId IdType="pubmed">23527010</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlewska U., Bilska B., Zegar A., Brzoza P., Borek A., Murzyn K., Bochenska O., Morytko A., Kuleta P., Kozik A., et al. The antimicrobial activity of chemerin-derived peptide p4 requires oxidative conditions. J. Biol. Chem. 2019;294:1267–1278. doi: 10.1074/jbc.RA118.005495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005495</ArticleId><ArticleId IdType="pmc">PMC6349111</ArticleId><ArticleId IdType="pubmed">30504221</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H.Y., Lee D.C., Chu S.H., Jeon J.Y., Lee M.K., Im J.A., Lee J.W. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. 2012;77:47–50. doi: 10.1111/j.1365-2265.2011.04217.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2011.04217.x</ArticleId><ArticleId IdType="pubmed">21895733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferland D.J., Mullick A.E., Watts S.W. Chemerin as a Driver of Hypertension: A Consideration. Am. J. Hypertens. 2020;33:975–986. doi: 10.1093/ajh/hpaa084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpaa084</ArticleId><ArticleId IdType="pmc">PMC7759724</ArticleId><ArticleId IdType="pubmed">32453820</ArticleId></ArticleIdList></Reference><Reference><Citation>Inci S., Aksan G., Dogan P. Chemerin as an independent predictor of cardiovascular event risk. Ther. Adv. Endocrinol. Metab. 2016;7:57–68. doi: 10.1177/2042018816629894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042018816629894</ArticleId><ArticleId IdType="pmc">PMC4820999</ArticleId><ArticleId IdType="pubmed">27092231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst M.C., Sinal C.J. Chemerin: At the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 2010;21:660–667. doi: 10.1016/j.tem.2010.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2010.08.001</ArticleId><ArticleId IdType="pubmed">20817486</ArticleId></ArticleIdList></Reference><Reference><Citation>John H., Hierer J., Haas O., Forssmann W.G. Quantification of angiotensin-converting-enzyme-mediated degradation of human chemerin 145-154 in plasma by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Anal. Biochem. 2007;362:117–125. doi: 10.1016/j.ab.2006.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2006.12.001</ArticleId><ArticleId IdType="pubmed">17240345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader M. ACE2—Das missbrauchte Multitalent. Nephrologe. 2020;2020:375–380. doi: 10.1007/s11560-020-00448-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11560-020-00448-0</ArticleId><ArticleId IdType="pmc">PMC7362321</ArticleId><ArticleId IdType="pubmed">32837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkady M.M., Abdel-Messeih P.L., Nosseir N.M. Assessment of Serum Levels of the Adipocytokine Chemerin in Colorectal Cancer Patients. J. Med. Biochem. 2018;37:313–319. doi: 10.1515/jomb-2017-0062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jomb-2017-0062</ArticleId><ArticleId IdType="pmc">PMC6298460</ArticleId><ArticleId IdType="pubmed">30598628</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Ponce F., Gamez-Nava J.I., Perez-Guerrero E.E., Saldana-Cruz A.M., Vazquez-Villegas M.L., Ponce-Guarneros J.M., Huerta M., Trujillo X., Contreras-Haro B., Rocha-Munoz A.D., et al. Serum chemerin levels: A potential biomarker of joint inflammation in women with rheumatoid arthritis. PLoS ONE. 2021;16:e0255854. doi: 10.1371/journal.pone.0255854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255854</ArticleId><ArticleId IdType="pmc">PMC8432803</ArticleId><ArticleId IdType="pubmed">34506500</ArticleId></ArticleIdList></Reference><Reference><Citation>Acewicz M., Kasacka I. Chemerin activity in selected pathological states of human body—A systematic review. Adv. Med. Sci. 2021;66:270–278. doi: 10.1016/j.advms.2021.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2021.05.002</ArticleId><ArticleId IdType="pubmed">34082283</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampela I., Christodoulatos G.S., Vallianou N., Tsilingiris D., Chrysanthopoulou E., Skyllas G., Antonakos G., Marinou I., Vogiatzakis E., Armaganidis A., et al. Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study. Biomolecules. 2022;12:301. doi: 10.3390/biom12020301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12020301</ArticleId><ArticleId IdType="pmc">PMC8869693</ArticleId><ArticleId IdType="pubmed">35204801</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn P., Metzing U.B., Steidl R., Romeike B., Rauchfuss F., Sponholz C., Thomas-Ruddel D., Ludewig K., Birkenfeld A.L., Settmacher U., et al. Chemerin in peritoneal sepsis and its associations with glucose metabolism and prognosis: A translational cross-sectional study. Crit. Care. 2016;20:39. doi: 10.1186/s13054-016-1209-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1209-5</ArticleId><ArticleId IdType="pmc">PMC4751629</ArticleId><ArticleId IdType="pubmed">26873079</ArticleId></ArticleIdList></Reference><Reference><Citation>Amend P., Mester P., Schmid S., Muller M., Buechler C., Pavel V. Plasma Chemerin Is Induced in Critically Ill Patients with Gram-Positive Infections. Biomedicines. 2023;11:1779. doi: 10.3390/biomedicines11071779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11071779</ArticleId><ArticleId IdType="pmc">PMC10376393</ArticleId><ArticleId IdType="pubmed">37509420</ArticleId></ArticleIdList></Reference><Reference><Citation>Khot W.Y., Nadkar M.Y. The 2019 Novel Coronavirus Outbreak—A Global Threat. J. Assoc. Physicians India. 2020;68:67–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32138488</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker T., Schell C.O., Petersen D.B., Sawe H., Khalid K., Mndolo S., Rylance J., McAuley D.F., Roy N., Marshall J., et al. Essential care of critical illness must not be forgotten in the COVID-19 pandemic. Lancet. 2020;395:1253–1254. doi: 10.1016/S0140-6736(20)30793-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30793-5</ArticleId><ArticleId IdType="pmc">PMC7270584</ArticleId><ArticleId IdType="pubmed">32246914</ArticleId></ArticleIdList></Reference><Reference><Citation>Zsichla L., Muller V. Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses. 2023;15:175. doi: 10.3390/v15010175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010175</ArticleId><ArticleId IdType="pmc">PMC9863423</ArticleId><ArticleId IdType="pubmed">36680215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez-Samaniego L., Bighelli F., Uson C., Caravaca C., Fernandez Carrillo C., Romero M., Barreales M., Perello C., Madejon A., Marcos A.C., et al. Elevation of Liver Fibrosis Index FIB-4 Is Associated with Poor Clinical Outcomes in Patients with COVID-19. J. Infect. Dis. 2020;222:726–733. doi: 10.1093/infdis/jiaa355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa355</ArticleId><ArticleId IdType="pmc">PMC7337860</ArticleId><ArticleId IdType="pubmed">32563190</ArticleId></ArticleIdList></Reference><Reference><Citation>Walia D., Saraya A., Gunjan D. COVID-19 in patients with pre-existing chronic liver disease–predictors of outcomes. World J. Virol. 2023;12:30–43. doi: 10.5501/wjv.v12.i1.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v12.i1.30</ArticleId><ArticleId IdType="pmc">PMC9896592</ArticleId><ArticleId IdType="pubmed">36743659</ArticleId></ArticleIdList></Reference><Reference><Citation>Aluganti Narasimhulu C., Singla D.K. Mechanisms of COVID-19 pathogenesis in diabetes. Am. J. Physiol. Heart Circ. Physiol. 2022;323:H403–H420. doi: 10.1152/ajpheart.00204.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00204.2022</ArticleId><ArticleId IdType="pmc">PMC9359655</ArticleId><ArticleId IdType="pubmed">35776683</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., Labrique A., Mohan D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE. 2021;16:e0247461. doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Izcovich A., Ragusa M.A., Tortosa F., Lavena Marzio M.A., Agnoletti C., Bengolea A., Ceirano A., Espinosa F., Saavedra E., Sanguine V., et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS ONE. 2020;15:e0241955. doi: 10.1371/journal.pone.0241955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241955</ArticleId><ArticleId IdType="pmc">PMC7671522</ArticleId><ArticleId IdType="pubmed">33201896</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ashcroft T., Chung A., Dighero I., Dozier M., Horne M., McSwiggan E., Shamsuddin A., Nair H. Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis. J. Glob. Health. 2021;11:10001. doi: 10.7189/jogh.11.10001.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.11.10001</ArticleId><ArticleId IdType="pmc">PMC7980087</ArticleId><ArticleId IdType="pubmed">33767855</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng M., He J., Xue Y., Yang X., Liu S., Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. J. Cardiovasc. Pharmacol. 2021;78:e648–e655. doi: 10.1097/FJC.0000000000001116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001116</ArticleId><ArticleId IdType="pmc">PMC8562915</ArticleId><ArticleId IdType="pubmed">34321401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukla M., Menzyk T., Dembinski M., Winiarski M., Garlicki A., Bociaga-Jasik M., Skonieczna M., Hudy D., Maziarz B., Kusnierz-Cabala B., et al. Anti-inflammatory adipokines: Chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes. Sci. Rep. 2021;11:21514. doi: 10.1038/s41598-021-00928-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00928-w</ArticleId><ArticleId IdType="pmc">PMC8563971</ArticleId><ArticleId IdType="pubmed">34728695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavis P., Morra S., Orte Cano C., Albayrak N., Corbiere V., Olislagers V., Dauby N., Del Marmol V., Marchant A., Decaestecker C., et al. Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality. Front. Immunol. 2022;13:941663. doi: 10.3389/fimmu.2022.941663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.941663</ArticleId><ArticleId IdType="pmc">PMC9412239</ArticleId><ArticleId IdType="pubmed">36032171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulicka-Grodzicka J., Surdacki A., Surmiak M., Sanak M., Wizner B., Sydor W., Bociaga-Jasik M., Strach M., Korkosz M., Skladany L., et al. Chemerin as a Potential Marker of Resolution of Inflammation in COVID-19 Infection. Biomedicines. 2022;10:2462. doi: 10.3390/biomedicines10102462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102462</ArticleId><ArticleId IdType="pmc">PMC9599036</ArticleId><ArticleId IdType="pubmed">36289725</ArticleId></ArticleIdList></Reference><Reference><Citation>Esendagli D., Topcu D., Gul E., Alperen C., Sezer R., Erol C., Akcay S. Can adipokines predict clinical prognosis and post-COVID lung sequelae? Respir. Investig. 2023;61:618–624. doi: 10.1016/j.resinv.2023.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2023.06.001</ArticleId><ArticleId IdType="pubmed">37433250</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X., Cheng Y., Zhang G., Wang B. Chemerin in inflammatory diseases. Clin. Chim. Acta. 2021;517:41–47. doi: 10.1016/j.cca.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.02.010</ArticleId><ArticleId IdType="pubmed">33631197</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal T., Buechler C. Adipokines as Diagnostic and Prognostic Markers for the Severity of COVID-19. Biomedicines. 2023;11:1302. doi: 10.3390/biomedicines11051302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11051302</ArticleId><ArticleId IdType="pmc">PMC10215701</ArticleId><ArticleId IdType="pubmed">37238973</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel V., Rath U., Schmid S., Krautbauer S., Keller D., Amend P., Muller M., Mester P., Buechler C. Serum Adiponectin Predicts COVID-19 Severity. Biomedicines. 2024;12:1043. doi: 10.3390/biomedicines12051043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12051043</ArticleId><ArticleId IdType="pmc">PMC11117573</ArticleId><ArticleId IdType="pubmed">38791005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta. 2007;380:24–30. doi: 10.1016/j.cca.2007.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2007.01.026</ArticleId><ArticleId IdType="pmc">PMC2755046</ArticleId><ArticleId IdType="pubmed">17343838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone R.C. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273:155–156. doi: 10.1001/jama.1995.03520260077036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520260077036</ArticleId><ArticleId IdType="pubmed">7799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M., Rajnik M., Aleem A., Dulebohn S.C., Napoliet R.D.  StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2024.  [(accessed on 14 August 2024)]. Features, Evaluation, and Treatment of Coronavirus (COVID-19) Available online:  https://www.ncbi.nlm.nih.gov/books/NBK554776/</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C.M., French C., Machado F.R., McIntyre L., Ostermann M., Prescott H.C., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit. Care Med. 2021;49:e1063–e1143. doi: 10.1097/CCM.0000000000005337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005337</ArticleId><ArticleId IdType="pubmed">34605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakike E., Giamarellos-Bourboulis E.J., Kyprianou M., Fleischmann-Struzek C., Pletz M.W., Netea M.G., Reinhart K., Kyriazopoulou E. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. Crit. Care Med. 2021;49:2042–2057. doi: 10.1097/CCM.0000000000005195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005195</ArticleId><ArticleId IdType="pmc">PMC8594513</ArticleId><ArticleId IdType="pubmed">34259663</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn P., von Loeffelholz C., Forkert F., Stengel S., Reuken P., Aschenbach R., Stallmach A., Bruns T. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. Sci. Rep. 2018;8:9242. doi: 10.1038/s41598-018-27543-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27543-6</ArticleId><ArticleId IdType="pmc">PMC6006249</ArticleId><ArticleId IdType="pubmed">29915268</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschel G., Grimm J., Gulow K., Muller M., Buechler C., Weigand K. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics. 2020;10:974. doi: 10.3390/diagnostics10110974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10110974</ArticleId><ArticleId IdType="pmc">PMC7699464</ArticleId><ArticleId IdType="pubmed">33228201</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokdemir G.S., Gokdemir M.T., Arac S., Yokus B. Prognostic significance of the chemerin level in coronavirus disease 2019 patients. Medicine. 2024;103:e37743. doi: 10.1097/MD.0000000000037743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000037743</ArticleId><ArticleId IdType="pmc">PMC10994447</ArticleId><ArticleId IdType="pubmed">38579052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawicka K., Michalska-Jakubus M., Potembska E., Kowal M., Pietrzak A., Krasowska D. Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis. Postepy Dermatol. Alergol. 2019;36:551–565. doi: 10.5114/ada.2018.79104.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ada.2018.79104</ArticleId><ArticleId IdType="pmc">PMC6906965</ArticleId><ArticleId IdType="pubmed">31839772</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiterer M., Rajan M., Gomez-Banoy N., Lau J.D., Gomez-Escobar L.G., Ma L., Gilani A., Alvarez-Mulett S., Sholle E.T., Chandar V., et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021;33:2174–2188.e2175. doi: 10.1016/j.cmet.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8443335</ArticleId><ArticleId IdType="pubmed">34599884</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijmael M., Janssens N., le Cessie S., van Dooren Y., Koster T., Karim F. Coronavirus disease 2019 and peripheral blood eosinophil counts: A retrospective study. Infection. 2021;49:1325–1329. doi: 10.1007/s15010-021-01710-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01710-w</ArticleId><ArticleId IdType="pmc">PMC8500265</ArticleId><ArticleId IdType="pubmed">34625911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B.D., Yang J.L., Xie Y., Tang X.L. Relationship between blood eosinophil levels and COVID-19 mortality. World Allergy Organ. J. 2021;14:100521. doi: 10.1016/j.waojou.2021.100521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.waojou.2021.100521</ArticleId><ArticleId IdType="pmc">PMC7877210</ArticleId><ArticleId IdType="pubmed">33589865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Zhao X.F., Chen X.L., Liu C.Y. Early decrease in blood lymphocyte count is associated with poor prognosis in COVID-19 patients: A retrospective cohort study. BMC Pulm. Med. 2023;23:453. doi: 10.1186/s12890-023-02767-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-023-02767-z</ArticleId><ArticleId IdType="pmc">PMC10662697</ArticleId><ArticleId IdType="pubmed">37986163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghenu M.I., Dragos D., Manea M.M., Ionescu D., Negreanu L. Pathophysiology of sepsis-induced cholestasis: A review. JGH Open. 2022;6:378–387. doi: 10.1002/jgh3.12771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12771</ArticleId><ArticleId IdType="pmc">PMC9218521</ArticleId><ArticleId IdType="pubmed">35774351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawood A.A., Aboelezz M.A., Elnoamany M.F. Chemerin levels in patients with coronary artery disease. Menoufia Med. J. 2020;33:288–294. doi: 10.4103/mmj.mmj_127_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/mmj.mmj_127_19</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadamuz J.S., Shooshtari A., Qato D.M. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015-2020. BMJ Open. 2022;12:e061350. doi: 10.1136/bmjopen-2022-061350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061350</ArticleId><ArticleId IdType="pmc">PMC9462115</ArticleId><ArticleId IdType="pubmed">36691204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke T., Picker N., Mueller S., Geier S., Foersch J., Aberle J., Martin S., Riedl M., Gabler M. Real-world insulin therapy in German type 2 diabetes mellitus patients: Patient characteristics, treatment patterns, and insulin dosage. Diabetes Metab. Syndr. Obes. 2019;12:1225–1237. doi: 10.2147/DMSO.S214288.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DMSO.S214288</ArticleId><ArticleId IdType="pmc">PMC6664320</ArticleId><ArticleId IdType="pubmed">31440070</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow R., Im J., Chiu N., Chiu L., Aggarwal R., Lee J., Choi Y.G., Prsic E.H., Shin H.J. The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2021;16:e0253576. doi: 10.1371/journal.pone.0253576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253576</ArticleId><ArticleId IdType="pmc">PMC8224908</ArticleId><ArticleId IdType="pubmed">34166458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao U.S., Law C.F., Baptista-Hon D.T., Tomlinson B. Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. J. Clin. Med. 2022;11:5454. doi: 10.3390/jcm11185454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11185454</ArticleId><ArticleId IdType="pmc">PMC9501062</ArticleId><ArticleId IdType="pubmed">36143101</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal T., Nguyen M.K.L., Buechler C. Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry. Life Sci. Alliance. 2024;7:e202302453. doi: 10.26508/lsa.202302453.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202302453</ArticleId><ArticleId IdType="pmc">PMC10883773</ArticleId><ArticleId IdType="pubmed">38388172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L., Wang N., Van Vark-Van Der Zee L., Van Lennep J.R., Mulder M., Lu X., Danser A.H., Verdonk K. Statins, but Not Pcsk9 Inhibitors, Reduce the Adipokine Chemerin in Familial Hypercholesterolemia: Focus on Lipoprotein Subfractions. Atherosclerosis. 2023;379:S173. doi: 10.1016/j.atherosclerosis.2023.06.583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2023.06.583</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson S.M., Fenno S.L., Barzilai N., Kuchel G., Bartley J.M., Justice J.N., Buse J.B., Bramante C.T. Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2. Diabetes Care. 2023;46:1432–1442. doi: 10.2337/dc22-2539.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-2539</ArticleId><ArticleId IdType="pmc">PMC10300519</ArticleId><ArticleId IdType="pubmed">37339345</ArticleId></ArticleIdList></Reference><Reference><Citation>Avogaro A., Bonora B., Fadini G.P. Managing diabetes in diabetic patients with COVID: Where do we start from? Acta Diabetol. 2021;58:1441–1450. doi: 10.1007/s00592-021-01739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-021-01739-1</ArticleId><ArticleId IdType="pmc">PMC8231743</ArticleId><ArticleId IdType="pubmed">34173070</ArticleId></ArticleIdList></Reference><Reference><Citation>Krautbauer S., Wanninger J., Eisinger K., Hader Y., Beck M., Kopp A., Schmid A., Weiss T.S., Dorn C., Buechler C. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp. Mol. Pathol. 2013;95:199–205. doi: 10.1016/j.yexmp.2013.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2013.07.009</ArticleId><ArticleId IdType="pubmed">23906870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B.K., Chen J., Farhatullah S., Adya R., Kaur J., Heutling D., Lewandowski K.C., O'Hare J.P., Lehnert H., Randeva H.S. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes. 2009;58:1971–1977. doi: 10.2337/db08-1528.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-1528</ArticleId><ArticleId IdType="pmc">PMC2731540</ArticleId><ArticleId IdType="pubmed">19502420</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohl R., Haberl E.M., Rein-Fischboeck L., Zimny S., Neumann M., Aslanidis C., Schacherer D., Krautbauer S., Eisinger K., Weiss T.S., et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur. J. Clin. Investig. 2017;47:7–18. doi: 10.1111/eci.12695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.12695</ArticleId><ArticleId IdType="pubmed">27797398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonikman D., Kustovs D. Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic. Medicina. 2023;59:1810. doi: 10.3390/medicina59101810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina59101810</ArticleId><ArticleId IdType="pmc">PMC10608676</ArticleId><ArticleId IdType="pubmed">37893528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan D., Robards K., Prenzler P.D., Kendall M. Recent and potential developments in the analysis of urine: A review. Anal. Chim. Acta. 2011;684:8–20. doi: 10.1016/j.aca.2010.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aca.2010.10.035</ArticleId><ArticleId IdType="pubmed">21167980</ArticleId></ArticleIdList></Reference><Reference><Citation>Huart J., Bouquegneau A., Lutteri L., Erpicum P., Grosch S., Resimont G., Wiesen P., Bovy C., Krzesinski J.M., Thys M., et al. Proteinuria in COVID-19: Prevalence, characterization and prognostic role. J. Nephrol. 2021;34:355–364. doi: 10.1007/s40620-020-00931-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-020-00931-w</ArticleId><ArticleId IdType="pmc">PMC7823174</ArticleId><ArticleId IdType="pubmed">33484426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S., Zhao Y., Wang F., Chen Y., Kaminga A.C., Xu H. Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine. 2021;100:e24971. doi: 10.1097/MD.0000000000024971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024971</ArticleId><ArticleId IdType="pmc">PMC9281964</ArticleId><ArticleId IdType="pubmed">33761654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng W.H., Tipih T., Makoah N.A., Vermeulen J.G., Goedhals D., Sempa J.B., Burt F.J., Taylor A., Mahalingam S. Comorbidities in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis. MBio. 2021;12:10–1128. doi: 10.1128/mBio.03647-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.03647-20</ArticleId><ArticleId IdType="pmc">PMC7885108</ArticleId><ArticleId IdType="pubmed">33563817</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisinger K., Krautbauer S., Wiest R., Weiss T.S., Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp. Mol. Pathol. 2015;98:208–213. doi: 10.1016/j.yexmp.2015.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2015.01.010</ArticleId><ArticleId IdType="pubmed">25595667</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurbuz B., Guldiken N., Reuken P., Fu L., Remih K., Preisinger C., Bruha R., Lenicek M., Petrtyl J., Reissing J., et al. Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis. Hepatol. Int. 2023;17:698–708. doi: 10.1007/s12072-022-10473-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-022-10473-x</ArticleId><ArticleId IdType="pmc">PMC10224844</ArticleId><ArticleId IdType="pubmed">36652164</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Castillo M., Rosique-Oramas D., Medina-Avila Z., Perez-Hernandez J.L., Higuera-De la Tijera F., Santana-Vargas D., Montalvo-Jave E.E., Sanchez-Avila F., Torre A., Kershenobich D., et al. Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression. Mol. Cell Biochem. 2020;469:65–75. doi: 10.1007/s11010-020-03728-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-03728-4</ArticleId><ArticleId IdType="pubmed">32301061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>